TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation June 22, 2026
TScan Therapeutics and Cellares Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies June 4, 2026
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update May 12, 2026
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update March 5, 2026
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03 February 27, 2026
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition December 10, 2025
